73227-97-1

Usage

Uses

Used in Pharmaceutical Synthesis:
4-BROMO-3-(4-NITROPHENYL)-1H-PYRAZOLE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of various drugs. The presence of the bromine and nitrophenyl groups allows for further chemical modifications, enhancing the compound's reactivity and potential therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, 4-BROMO-3-(4-NITROPHENYL)-1H-PYRAZOLE is utilized as a precursor in the development of pesticides and other agrochemicals. Its chemical properties make it suitable for creating compounds that can effectively control pests and diseases in agriculture, thereby contributing to increased crop yields and food security.
Used in Chemical Research:
4-BROMO-3-(4-NITROPHENYL)-1H-PYRAZOLE serves as a valuable research tool in chemical studies, where it is employed to investigate various chemical reactions and mechanisms. Its unique structure allows researchers to explore its reactivity and potential applications in the synthesis of new compounds.
Used in Biological Studies:
As a research tool in biological studies, 4-BROMO-3-(4-NITROPHENYL)-1H-PYRAZOLE is used to examine its potential biological activities, such as antimicrobial and anticancer properties. Its presence of bromine and nitrophenyl groups may contribute to its ability to interact with biological targets, making it a promising candidate for further research and development in the field of medicine.
Used in Antimicrobial Applications:
4-BROMO-3-(4-NITROPHENYL)-1H-PYRAZOLE is studied for its potential as an antimicrobial agent, where it may be used to combat various types of bacteria and other microorganisms. Its chemical structure allows it to potentially disrupt microbial processes, offering a new avenue for the development of antimicrobial drugs.
Used in Anticancer Research:
In the field of oncology, 4-BROMO-3-(4-NITROPHENYL)-1H-PYRAZOLE is being investigated for its potential as an anticancer agent. Its unique structure may enable it to interact with cellular targets, inhibiting the growth and proliferation of cancer cells, and offering a new approach to cancer treatment.

Upstream product

• 20583-31-7 5⁽³⁾-(4-nitrophenyl)-1H-pyrazole 
• 20583-31-7 3-(4-nitrophenyl)-1H-pyrazole 

Downstream Products

• 927653-45-0 4-bromo-1-methyl-3-(4-nitrophenyl)-1H-pyrazole 
• 927653-48-3 3-(4-nitrophenyl)-1-(2-hydroxyethyl)-4-bromo-1H-pyrazole 
• 1019011-03-0 C₉H₈BrN₃ 
• 942920-24-3 4-bromo-1-{[4-(methyloxy)phenyl]methyl}-3-(4-nitrophenyl)-1H-pyrazole 
• 942920-38-9 4-bromo-3-(4-nitrophenyl)-1-(2-propen-1-yl)-1H-pyrazole 
• 942920-12-9 4-bromo-1-ethyl-3-(4-nitrophenyl)-1H-pyrazole 
• 942920-28-7 1,1-dimethylethyl [4-bromo-3-(4-nitrophenyl)-1H-pyrazol-1-yl]acetate 

Relevant academic research and scientific papers

Discovery of GSK1070916, a potent and selective inhibitor of aurora B/C kinase

The Aurora kinases play critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. Selective inhibitors may provide a new therapy for the treatment of tumors with Aurora kinase amplification. Herein we describe our lead optimization efforts within a 7-azaindole-based series culminating in the identification of GSK1070916 (17k). Key to the advancement of the series was the introduction of a 2-aryl group containing a basic amine onto the azaindole leading to significantly improved cellular activity. Compound 17k is a potent and selective ATP-competitive inhibitor of Aurora B and C with Ki* values of 0.38 ± 0.29 and 1.5 ± 0.4 nM, respectively, and is >250-fold selective over Aurora A. Biochemical characterization revealed that compound 17k has an extremely slow dissociation half-life from Aurora B (>480 min), distinguishing it from clinical compounds 1 and 2. In vitro treatment of A549 human lung cancer cells with compound 17k results in a potent antiproliferative effect (EC50 = 7 nM). Intraperitoneal administration of 17k in mice bearing human tumor xenografts leads to inhibition of histone H3 phosphorylation at serine 10 in human colon cancer (Colo205) and tumor regression in human leukemia (HL-60). Compound 17k is being progressed to human clinical trials.

Two convenient regioselective syntheses of 1-N-alkyl-3-aryl-4-[pyrimidin-4-yl]-pyrazoles

Two regioselective synthetic routes for 1-N-alkyl-3-aryl-4-[pyrimidin-4-yl]-pyrazoles of generic formula 1 were developed. These highly efficient and scalable routes circumvent the generally observed poor regioselectivity for the pyrazole alkylation.

AZAINDOLE INHIBITORS OF AURORA KINASES

The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including s

PYRIMIDINYL-PYRAZOLE INHIBITORS OF AURORA KINASES

The present invention provides a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a combination thereof, wherein the substituents are as defined herein. The present invention also relates to a co